Nurix Therapeutics announces presentation of new data on NX-1607

Nurix Therapeutics (NRIX) announced the presentation of new translational data from its ongoing Phase 1 study of NX-1607, an oral, first-in-class inhibitor of Casitas B-lineage lymphoma proto-oncogene B, at the Society for Immunotherapy of Cancer 2025 Annual Meeting which is being held November 5-9, 2025, in National Harbor, MD. Key Findings: Dose-dependent pharmacology and immune activation: NX-1607 demonstrated dose-dependent pharmacokinetics and pharmacodynamic modulation of the proximal biomarker pHS1, confirming target engagement and inhibition of CBL-B-mediated signaling. Peripheral immune activation linked to clinical benefit: Patients with stable disease exhibited a greater enrichment of circulating PD-1 CD8 T cells expressing Ki67 and ICOS markers compared with those with progressive disease, demonstrating active TCR engagement and antitumor immune responsiveness. Remodeling of the tumor microenvironment: In a case study of a heavily pretreated mCRPC patient, NX-1607 treatment achieved a best response of stable disease. Transcriptomic evidence of immune pathway engagement: RNA sequencing analyses demonstrated dose-dependent enrichment of immune signaling pathways, including interferon response, antigen presentation, and effector T cell activation, further supporting a mechanistic link between NX-1607 exposure and immune activation.